BMGL on Nasdaq
Basel Medical Group Ltd
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Cardiff Lexington Corp, HealthLynked Corp or Concord Medical Services Holdings Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$8.9M
Out of $8.9M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| Revenue | 11.3M SGD | 10.1M SGD |
| Other income | 1.8M SGD | 461.0K SGD |
| Consumables, medical supplies and other related expenses | -2.6M SGD | -2.2M SGD |
| Employee benefit expenses | -6.4M SGD | -3.6M SGD |
| Depreciation expense | -1.2M SGD | -528.7K SGD |
| Rent expense | -141.1K SGD | -3.2K SGD |
| Other operating expense | -3.3M SGD | -1.5M SGD |
| Impairment loss on goodwill | -10.3M SGD | |
| Finance cost | -203.9K SGD | -176.2K SGD |
| (Loss)/Profit before tax | -11.1M SGD | 2.4M SGD |
| Income tax expense | 417.4K SGD | -331.8K SGD |
| (Loss)/Profit after tax | -10.6M SGD | 2.1M SGD |
| (Loss)/Profit for the year, representing total comprehensive income for the year | -10.6M SGD | 2.1M SGD |
| Owners of the Company | -10.6M SGD | 2.1M SGD |
| Non-controlling interests | -501 SGD | |
| (Loss)/Profit for the year | -10.6M SGD | 2.1M SGD |
| Basic | -0.45 SGD | 0.13 SGD |
| Diluted | -0.57 SGD | 0.13 SGD |
| Basic | 18.8M shares | 16.2M shares |
| Diluted | 18.8M shares | 16.2M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Right-of-use-assets | 4.9M SGD | 23.5K SGD | |
| Property and equipment | 388.7K SGD | 34.5K SGD | |
| Deferred tax assets | 47.9K SGD | 77.0K SGD | |
| Total Non-current assets | 5.4M SGD | 135.0K SGD | |
| Inventories | 489.1K SGD | 72.0K SGD | |
| Trade and other receivables | 9.5M SGD | 2.0M SGD | |
| Cash and cash equivalents | 3.0M SGD | 2.0M SGD | 1.2M SGD |
| Deferred offering costs | 31.8K SGD | 1.6M SGD | |
| Current tax assets | 239.4K SGD | ||
| Total Current assets | 13.3M SGD | 16.2M SGD | |
| Total assets | 18.7M SGD | 16.3M SGD | |
| Deferred tax liabilities | 123.8K SGD | ||
| Borrowings | 3.0M SGD | 1.6M SGD | |
| Total Non-current liabilities | 3.1M SGD | 1.6M SGD | |
| Trade and other payables | 6.6M SGD | 2.6M SGD | |
| Borrowings | 2.1M SGD | 2.7M SGD | |
| Amount due to related parties | 1.5M SGD | 1.3M SGD | |
| Amount due to a former director | 111.5K SGD | ||
| Asset retirement obligation | 15.0K SGD | 15.0K SGD | |
| Provision for income tax | 443.3K SGD | ||
| Total Current liabilities | 10.2M SGD | 7.2M SGD | |
| Total liabilities | 13.2M SGD | 8.7M SGD | |
| NET ASSETS | 5.4M SGD | 7.6M SGD | |
| Share capital | 34.2M SGD | 24.5M SGD | |
| Merger reserve arising from group restructuring | -24.5M SGD | -24.5M SGD | |
| Retained earnings | -3.9M SGD | 7.6M SGD | |
| Translation reserve | -463.8K SGD | ||
| Non-controlling interest | 3.5K SGD | ||
| Total equity | 5.4M SGD | 7.6M SGD | 5.5M SGD |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| (Loss)/Profit before tax | -11.1M SGD | 2.4M SGD |
| Bad debts written off | 602.3K SGD | |
| Reversal of estimated credit losses | -55.7K SGD | |
| Provision for estimated credit losses | 277.1K SGD | 50.2K SGD |
| Depreciation of property and equipment | 107.7K SGD | 30.1K SGD |
| Amortisation of right-of-use assets | 1.1M SGD | 498.6K SGD |
| Fixed asset written off | 206.3K SGD | |
| Impairment loss on goodwill | 10.3M SGD | |
| Interest expense | 203.9K SGD | 176.2K SGD |
| Operating cash flows before changes in working capital | 1.8M SGD | 3.1M SGD |
| Inventories | -304.3K SGD | 22.6K SGD |
| Trade and other receivables | -8.7M SGD | -415.1K SGD |
| Trade and other payables | 4.0M SGD | 387.7K SGD |
| Cash (used in)/ generated from operations | -3.2M SGD | 3.1M SGD |
| Interest paid | -648.3K SGD | -176.2K SGD |
| Income tax paid | -203.9K SGD | -413.6K SGD |
| Net cash (used in)/generated from operating activities | -4.0M SGD | 2.5M SGD |
| Acquisition of property and equipment | -556.9K SGD | -7.9K SGD |
| Acquisition of subsidiary | -10.3M SGD | |
| Cash provided by/ (used in) investing activities | -10.9M SGD | -7.9K SGD |
| Deferred offering costs | 1.6M SGD | -1.6M SGD |
| Decrease in amount due from a director | 1.3M SGD | |
| Increase in amount due to related parties | 138.9K SGD | 1.3M SGD |
| Decrease/(Increase) in amount due from related parties | 10.6M SGD | -73 SGD |
| Proceeds from borrowings | 4.0M SGD | |
| Payment of principal portion of lease liabilities | -1.3M SGD | -566.0K SGD |
| Write off of Right-of-use assets | 183.2K SGD | |
| Repayment of borrowings | -8.3M SGD | -2.4M SGD |
| (Decrease)/Increase in amount due to former director | -111.5K SGD | 111.5K SGD |
| Non-controlling interest contributions | 3.5K SGD | |
| Share issuance | 9.8M SGD | |
| Net cash generated from/(used in) financing activities | 16.5M SGD | -1.8M SGD |
| Net increase/(decrease) in cash and cash equivalents | 1.6M SGD | 733.6K SGD |
| Effects of currency translation on cash and cash equivalents | -463.8K SGD |
Recent filings
- Oct 13, 20266-K
- Oct 9, 20266-K
- Oct 8, 2026424B4
- Oct 1, 20263
- Sep 29, 2026EFFECT
- Sep 23, 2026F-1/A
- Sep 17, 2026F-1
- Sep 2, 20266-K
- Aug 10, 20266-K
- Jul 31, 2026DRS
- Jul 22, 20263
- Jul 10, 20266-K
- Jun 26, 20266-K
- Jun 10, 20266-K
- Jun 5, 20266-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3